---
title: "Phathom Pharmaceuticals, Inc. (PHAT.US) — 公司概況"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/PHAT.US/overview.md"
symbol: "PHAT.US"
name: "Phathom Pharmaceuticals, Inc."
parent: "https://longbridge.com/zh-HK/quote/PHAT.US.md"
datetime: "2026-04-17T10:21:21.275Z"
locales:
  - [en](https://longbridge.com/en/quote/PHAT.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PHAT.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PHAT.US/overview.md)
---

# Phathom Pharmaceuticals, Inc. (PHAT.US) — 公司概況

## 基本資訊

| 項目 | 詳情 |
|------|--------|
| 行業 | 制藥 |
| 交易所 | US Market |
| 地址 | 100 Campus Drive, Suite 102, Florham Park, New Jersey, United States |
| 官網 | [www.phathompharma.com](https://www.phathompharma.com) |

## 公司簡介

Phathom Pharmaceuticals, Inc.是一家生物制藥公司，專注于在美國開發和商業化治療胃腸疾病的藥物。它開發的 VOQUEZNA 已完成針對成人侵蝕性胃食管反流病（GERD）及相關胃灼熱的 III 期臨床試驗；VOQUEZNA Triple Pak 和 VOQUEZNA Dual Pak 也已完成針對幽門螺桿菌的 III 期臨床試驗，以及 VOQUEZNA 和 vonoprazan 用于治療與非侵蝕性 GERD 和嗜酸性食管炎相關的成人和青少年的胃灼熱。該公司成立于 2018 年，總部位于新澤西州的 Florham Park

## 核心管理層

| 名稱 | 職位 |
|------|-------|
| Steven L. Basta | CEO, President & Director |
| Michael F. Cola | Independent chairman of the Board |
| David A. Socks | Co-Founder |
| Azmi Nabulsi | Co-Founder |
| Sanjeev Narula | Chief Financial & Business Officer |
| Anne Marie Cook | Chief Legal Officer & Corporate Secretary |
| Heidi Kunz Fields | Independent Director |
| Asit Parikh | Independent Director |
| James Newman Topper | Independent Director |

## 主要股東

| 名稱 | 佔比 | 報告日期 |
|------|-------|-------------|
| Frazier Life Sciences Management, LP | 15.69% | 2025-12-31 |
| Medicxi Ventures (UK) LLP | 9.40% | 2025-12-31 |
| Millennium Management LLC | 5.26% | 2026-03-06 |
| BlackRock, Inc. | 4.48% | 2025-12-31 |
| Abingworth LLP | 4.40% | 2025-12-31 |
| Invesco Ltd. | 4.38% | 2025-12-31 |
| The Vanguard Group, Inc. | 4.00% | 2025-12-31 |
| Ensign Peak Advisors, Inc. | 2.96% | 2025-12-31 |
| New Enterprise Associates, Inc. | 2.47% | 2025-12-31 |
| 683 Capital Management, LLC | 2.25% | 2025-12-31 |

## 業務構成

| 業務線 | 營收 | 佔比 |
|---------|---------|-------|
| 藥品 | 175110000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Phathom Pharmaceuticals, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "藥品",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## 地區分佈

| 地區 | 營收 | 佔比 |
|--------|---------|-------|
| 美國 | 175110000 | 100% |


---

> **免責聲明: 本文僅供參考，不構成任何投資建議。**